A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial

Ítems similars

• A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
  per: Pace, D, et al.
  Publicat: (2008)
• Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study.
  per: Khatami, A, et al.
  Publicat: (2012)
• Serogroup c meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
  per: Snape, M, et al.
  Publicat: (2006)
• Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants.
  per: Khatami, A, et al.
  Publicat: (2013)
• What are the implications for childhood pneumonia of successfully introducing hib and pneumococcal vaccines in developing countries?
  per: Scott, J, et al.
  Publicat: (2008)